Shared on 24 Jul 26
Fair value Decreased 82%HUMA: V012 Phase 3 Data Will Drive Dialysis Access Opportunity
15 viewsusers have viewed this narrative update
HumacyteHUMA
Fair Value
US$4
Share price24 Jul
US$0.684.9% undervalued intrinsic discount
1Y-67.83%
7D-15.79%
Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential
AN
Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls
Published
08 Jan 26
Updated
24 Jul 26
Views
377
Not Invested